Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Price:
20.08 USD
3.61%
Market Closed
Updated:
May 4, 2024
Section:
Relative Value
The Relative Value of one
KNSA
stock under the Base Case scenario is
38.31
USD.
Compared to the current market price of 20.08 USD,
Kiniksa Pharmaceuticals Ltd
is
Undervalued by 48%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
KNSA
Relative Value
Base Case
38.31
USD
Undervaluation 48%
Valuation Multiples
Multiples Across Competitors
KNSA Competitors Multiples
Kiniksa Pharmaceuticals Ltd Competitors
Kiniksa Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| BM |
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
1.4B USD | 4.7 | 163.7 | -42.9 | -39.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 5.3 | 60 | 13 | 19.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 5.9 | 24.8 | 17.9 | 26.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 8 | 26.5 | 17.8 | 19.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 10.5 | 28.6 | 22.8 | 23.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.6 | 21.6 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 2.9 | 166.8 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | 7 | -10.1 | -11 | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 3.3 | 27.1 | 13.9 | 17.4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
